Evaluation of Drug Utilization Patterns Using WHO Indicators in Patients with End-Stage Chronic Kidney Disease: A Cross-Sectional Study in Kirkuk, Iraq
DOI:
https://doi.org/10.54133/ajms.v11i1.3075Keywords:
Chronic kidney diseases, Drug utilization, Iraqi patients, Kirkuk, Prescribing patterns, WHO indicatorsAbstract
Background: Chronic kidney disease (CKD) is a challenging problem. Drug use evaluation is an important issue for the recommended medications. Objective: To assess drug utilization patterns among end-stage CKD patients in Kirkuk, Iraq, based on World Health Organization (WHO) prescribing indicators. Methods: A cross-sectional study was conducted in Kirkuk, Iraq, involving data collection from Al-Amal Centre for Dialysis. A hospital-based convenience sampling technique was used to recruit a total of 314 patients diagnosed with end-stage CKD (stage 5) from October 2025 to January 2026. Results: Most patients were less than 60 years of age (59.24%), with a mean age of 57.1 years, and a male predominance (60.51%). The mean number of comorbidities per patient was 2.9. The encountered comorbidities in CKD patients were hypertension (89%), anemia (88%), and diabetes mellitus (41%). The average number of drugs per prescription was 13, and antibiotics were 42.35%. About 79.96% of drugs prescribed are generics, and injectables represent 82.48%, while the percentage of drugs prescribed according to the essential drug list is 48.76%. Conclusions: There is a critical prevalence of polypharmacy and a dependence on non-essential medications, which significantly increases the risk of severe drug responses and financial burdens for patients with chronic kidney disease. The high incidence of generic prescriptions is a positive step toward lowering costs, but it is overshadowed by the overuse of injectables and antibiotics, as well as the excessive number of medications per prescription.
Downloads
References
Sujana CN, Niranjan MR, Parashivamurthy BM. A prospective observational study on drug utilization pattern in patients with chronic kidney disease at a tertiary care hospital. Glob J Res Anal. 2020;9(12):165-167.
Dema TS, Ahmed AU, Roy AS, Begum SA, Sattar S, Afrose R, et al. Drug prescribing patterns for chronic kidney disease in a tertiary care hospital of Bangladesh. Shaheed Syed Nazrul Islam Med Col J. 2025;10(2):85-95. doi: 10.69699/ssnimcj2025v10i2s2. DOI: https://doi.org/10.69699/ssnimcj2025v10i2s2
Memon BM, Khoso SA, Ateya AAE, Eltayeb LB. Evaluation of drug prescribing trends and drug-drug interactions among chronic kidney disease patients. J Biochem Technol. 2022;13(3):63-66. doi: 10.51847/ZF3KCjACdU. DOI: https://doi.org/10.51847/ZF3KCjACdU
Narayana Murthy BV, Satyanarayana V. Prescribing pattern of drugs in chronic kidney disease patients on hemodialysis at a tertiary care hospital. Int J Basic Clin Pharmacol. 2017;6:928-932. doi: 10.18203/2319-2003.ijbcp20171106. DOI: https://doi.org/10.18203/2319-2003.ijbcp20171106
Chenchula S, Gupta R, Gupta SK, Padmavathi R, Pathan S. Assessment of WHO core drug use indicators at a tertiary care Institute of National importance in India. Bioinformation. 2022;18(10):888-893. doi: 10.6026/97320630018888. DOI: https://doi.org/10.6026/97320630018888
Faiq MK. Prevalence of medication prescription patterns for Iraqi outpatients visiting otolaryngology clinics. Al-Mustaqbal J Pharm Med Sci. 2026;4(1):7-13. doi: 10.62846/3006-5909.1039. DOI: https://doi.org/10.62846/3006-5909.1039
Kanjariya D, Sinha A, Vaniya H, Rathva T, Makvana A. Evaluation of pharmacotherapeutic patterns in patients with renal impairment undergoing hemodialysis: A drug utilization study. Cureus. 2025;17(12):e99970. doi: 10.7759/cureus.99970. DOI: https://doi.org/10.7759/cureus.99970
Kamath L, Hema NG, Himamani S. A study of drug utilisation pattern in patients of chronic kidney disease at a tertiary care hospital. Int J Basic Clin Pharmacol. 2019;8:170-175. doi: 10.18203/2319-2003.ijbcp20190131. DOI: https://doi.org/10.18203/2319-2003.ijbcp20190131
Pratiksha, Shaurya R, Gehlot A, Sharma M. Observational study of prescription pattern according to WHO guidelines in chronic kidney disease patients in medicine out patient department at a tertiary care hospital. Eur J Pharm Med Res. 2023;10(3):242-245.
Pathak A, Gupta VK, Maurya A, Kumar A, Singh A. Assessment of drug prescribing pattern using WHO indicators in hospitalized patients at a tertiary care teaching hospital in rural area of India. Int J Basic Clin Pharmacol. 2016;5:651-655. doi: 10.18203/2319-2003.ijbcp20160983. DOI: https://doi.org/10.18203/2319-2003.ijbcp20160983
Cochran WG, (Editor), Sampling Techniques, (3rd ed.), New York: John Wiley & Sons; 1977.
Al-Jabri MM, Shastry CS, Chand S. Assessment of drug utilization pattern in chronic kidney disease patients in a tertiary care hospital based on who core drug use indicators. J Glob Pharma Technol. 2019;11(09):1-9.
World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bulletin of the World Health Organization. 2001;79(4):373- 374.
World Health Organization. How to investigate drug use in health facilities: selected drug use indicators. Geneva: World Health Organization; 1993. [cited 2025 Nov 30].
Ahlawat R, D’cruz S, Tiwari P. Drug utilization pattern in chronic kidney disease patients at a tertiary care public teaching hospital: Evidence from a cross-sectional study. J Pharm Care Health Syst. 2015;3(1):1-5. doi: 10.4172/2376-0419.1000149. DOI: https://doi.org/10.4172/2376-0419.1000149
Kanani NJ, Mistry VR, Rathva SJ. Drug utilization pattern in chronic kidney disease patients at a tertiary care teaching hospital. Innova Pharm Pharmacother. 2019;7(2):41-45.
Harshita, Thakur N, Yadav J, Monika, Gupta S, Verma I. Drug utilization pattern in chronic kidney disease associated comorbidities at a tertiary care hospital. J Young Pharmacists. 2023;15(4):743-747. doi: 10.5530/jyp.2023.15.102. DOI: https://doi.org/10.5530/jyp.2023.15.102
Demir E, Caliskan Y, Aliyeva N, Yilmaz O, Celik D, Akgul SU, Turkmen A. Importance of parental consanguinity and family history of kidney disease in the Turkish adult chronic kidney disease population: An epidemiologic study. Turk J Nephrol. 2024;33(4):333-341. doi: 10.5152/turkjnephrol.2024.22442. DOI: https://doi.org/10.5152/turkjnephrol.2024.22442
Bajait CS, Pimpalkhute SA, Sontakke SD, Jaiswal KM, Dawri AV. Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders. Indian J Pharmacol. 2014;46(1):35-39. doi: 10.4103/0253-7613.125163. DOI: https://doi.org/10.4103/0253-7613.125163
Alruqayb WS, Paudyal V, Malcolm P, Sarwar A, Aston J, Cox AR. Drug utilisation study in hospitalised chronic kidney disease patients, using World Health Organisation prescribing indicators: an observational study. J Pharm Policy Pract. 2024;17(1):2430436. doi: 10.1080/20523211.2024.2430436. DOI: https://doi.org/10.1080/20523211.2024.2430436
Sangeetha B, Thangamani S. Evaluation of drug utilization pattern in patients with chronic kidney disease. Biosci Biotech Res Asia. 2023;20(09):1065-1071. doi: 10.13005/bbra/3157. DOI: https://doi.org/10.13005/bbra/3157
Soon HC, Geppetti P, Lupi C, Kho BP. Medication safety, In: Donaldson L, Ricciardi W, Sheridan S, Tartaglia R, (Editors), Textbook of patient safety and clinical risk management. 2020:435-453. Available at: https://www.ncbi.nlm.nih.gov/books/NBK585609/ DOI: https://doi.org/10.1007/978-3-030-59403-9_31
Mason NA. Polypharmacy and medication-related complications in the chronic kidney disease patient. Curr Opin Nephrol Hypertens. 2011;20(5):492-497. doi: 10.1097/MNH.0b013e328349c261. DOI: https://doi.org/10.1097/MNH.0b013e328349c261
Schmidt IM, Hübner S, Nadal J, Titze S, Schmid M, Bärthlein B, et al. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. Clin Kidney J. 2019;12(5):663-672. doi: 10.1093/ckj/sfz046. DOI: https://doi.org/10.1093/ckj/sfz046
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-130. doi: 10.1038/ki.2009.188. DOI: https://doi.org/10.1038/ki.2009.188
Rakshana S, Selva P. A study on the prescription pattern among patients with chronic kidney disease at a tertiary care hospital. Curr Topics Pharmacol. 2019;23:1-9.
Faiq MK, Saleh ES, Fathalla OB. Lack of Association of the HMGA1 Gene Variants with Metabolic Syndrome Risk and Response to Oral Anti-Diabetic Drugs. Al-Kindy Col. Med. 2023 Aug. 30;19(2):141-6. DOI: https://doi.org/10.47723/kcmj.v19i2.915
Faiq MK, Saleh ES, Fathalla OB. Influence of the high mobility group A1 genetic polymorphism on indices of metabolic syndrome and insulin resistance in the Iraqi population: Case-control study. J Adv Biotechnol Exp Ther. 2023; 6(2): 326-336. DOI: https://doi.org/10.5455/jabet.2023.d129
Faiq MK, Saleh ES, Fathalla OB. High Serum High Mobility Group A1 (HMGA1) Levels are associated with Presence of Metabolic Syndrome: Case-Control Study. J Fac Med Baghdad. 2023 Apr. 27;65(1):53-8. DOI: https://doi.org/10.32007/jfacmedbagdad.6512036
Okawa Y, Mitsuhashi T, Tsuda T. The Asia-Pacific Body Mass Index Classification and New-Onset Chronic Kidney Disease in Non-Diabetic Japanese Adults: A Community-Based Longitudinal Study from 1998 to 2023. Biomedicines. 2025 Feb 5;13(2):373. DOI: https://doi.org/10.3390/biomedicines13020373
Faiq MK. Antibiotic resistance in bacterial species: A retrospective study of cultures in Kirkuk City, Iraq. Tikrit J Pharm Sci. 2025;19(1):18-29. doi: 10.25130/tjphs.2025.19.1.2.18.29. DOI: https://doi.org/10.25130/tjphs.2025.19.1.2.18.29
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).
